Skip to main content
SpringerPlus
Figure 3 | SpringerPlus

Figure 3

From: Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling

Figure 3

Results of a virtual clinical trial elucidating tamoxifen standard dose regimen. Box-whisker-plots indicate the percentiles 5, 25, 50, 75, and 95 of the population simulation results. Symbols represent CYP2D6 phenotype-specific plasma concentrations extracted from the literature of clinical trials performed in postmenopausal early breast cancer women and tamoxifen mono-therapy. Abbreviations used in diagram: tamoxifen (TAM), N-desmethyltamoxifen (NDM), 4-hydroxytamoxifen (4OH), endoxifen (END), cytochrome P450 2D6 (CYP2D6), extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM).

Back to article page